Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Biotechnology

Healthcare
$1.43 -2.40%

-$0.04 today

Market cap
$82.18M
Beta
3.23
P/E (TTM)
-2.2
EPS (TTM)
-$0.75
52W Low $1.62High $4.94

Volume 0.60M

Average 1.31M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$29.61M

FY 2025 · Annual

Investing Cash Flow

-$44.91M

FY 2025 · Annual

Financing Cash Flow

-$146,000.00

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Depreciation & Amortization205K508K437K343K325K
Deferred Income Tax2.18M0000
Stock-Based Compensation14.04M12.2M9.6M10.63M6.63M
Change in Working Capital7.02M(9.9M)3.69M(2.69M)(8.73M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.57M(2.23M)597K1.68M(3.43M)
Other Working Capital5.45M(7.67M)3.09M(4.38M)(5.3M)
Other Non-Cash Items2.01M3.28M2M(905K)9.02M
Operating Cash Flow(100.15M)(85.08M)(66.72M)(62.3M)29.61M
Capital Expenditures(2.71M)(192K)(33K)00
Acquisitions (Net)2.7M9K094K27K
Purchases of Investments(49.51M)(60.14M)(61.89M)(122.88M)(164.03M)
Sales of Investments182.83M113.69M78.17M139.75M119.02M
Other Investing Activities(2.7M)095K074K
Investing Cash Flow130.61M53.37M16.35M16.97M(44.91M)
Debt Repayment00000
Common Stock Issued729K177K71.85M24.49M(146K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0082K1.05M0
Financing Cash Flow729K177K71.93M25.55M(146K)
Effect of Forex Changes00000
Net Change in Cash31.19M(31.54M)21.56M(19.79M)(15.44M)
Free Cash Flow(102.86M)(85.27M)(66.75M)(62.3M)29.61M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$22.4M
+ D&A$325.0K
+ Stock-Based Comp$6.6M
+ Deferred Tax$0
- Working Capital-$8.7M
+ Other Non-Cash$9.0M
= Operating Cash Flow$29.6M
- Capex$0
= Free Cash Flow$29.6M

Analysis

FY2025 free cash flow is $29.6M. FCF conversion is 132.4% of net income. Operating cash flow was $29.6M, with capex of $0. The largest bridge item is Other Non-Cash at $9.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
4Statement of changes in beneficial ownershipSep 21, 2026
4Statement of changes in beneficial ownershipSep 21, 2026
8-KCurrent reportAug 5, 2026

Does BDTX generate free cash flow?

Black Diamond Therapeutics, Inc. (BDTX) generated $29.61M of free cash flow in fiscal 2025.

How much operating cash flow does BDTX produce?

Operating cash flow was $29.61M, before capital expenditures of $0.00.